

Ref: FOI/GS/ID 5151

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

17 January 2019

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Biologics and Biosimilar prescribing.

You asked:

Could you please provide me with the following numbers of patients treated for Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis in the last 12 months (latest 12 months possible) with the following drugs;

Abatacept (Orencia)

Adalimumab (Biosimilar)

Adalimumab (Humira)

Apremilast (Otezla)

Baricitinib (Olumiant)

Brodalumab (Kyntheum)

Certolizumab (Cimzia)

Dimethyl Fumarate (Skilarence)

Etanercept (Enbrel)

Etanercept Biosimilar (Benepali or Erelzi)

Golimumab (Simponi)

Guselkumab (Tremfya)

Infliximab (Remicade)

Infliximab Biosimilar (Inflectra, Remsima or Flixabi)

Ixekizumab (Taltz)

Rituximab (Mabthera)

Rituximab Biosimilar (Rixathon or Truxima)

Sarilumab (Kevzara)

Secukinumab (Cosentyx)

Tildrakizumab (Ilumetri)

Tocilizumab (Ro Actemra)

Tofacitinib (Xeljanz)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)

Trust response:

Number of patients treated	Rheumatoid Arthritis	Ankylosing Spondylitis	Psoriatic Arthritis	Psoriasis	Crohn's Disease	Ulcerative Colitis
TOTAL						
Abatacept (Orencia)	88	0	0	0	1	0
Adalimumab (Biosimilar)	0	0	0	0	0	0
Adalimumab (Humira)	145	84	73	0	128	26
Apremilast (Otezla)	0	0	2	0	0	0
Baricitinib (Olumiant)	6	0	0	0	0	0
Brodalumab (Kyntheum)	0	0	0	0	0	0
Certolizumab (Cimzia)	19	4	5	0	0	0
Dimethyl Fumarate (Skilarence)	0	0	0	0	0	0
Etanercept (Enbrel)	64	12	18	0	0	0
Etanercept Biosimilar (Benepali or Erelzi)	168	39	56	0	0	0
Golimumab (Simponi)	42	40	64	0	0	4
Guselkumab (Tremfya)	0	0	0	0	0	0
Infliximab (Remicade)	11	3	3	0	4	1
Infliximab Biosimilar (Inflectra, Remsima or Flixabi)	22	14	9	0	144	39
Ixekizumab (Taltz)	0	0	0	0	0	0
Rituximab (Mabthera)	5	0	1	0	0	0
Rituximab Biosimilar (Rixathon or Truxima)	115	1	0	0	0	0
Sarilumab	2	0	0	0	0	0

(Kevzara)						
Secukinumab (Cosentyx)	0	24	35	0	0	0
Tildrakizumab (Ilumetri)	0	0	0	0	0	0
Tocilizumab (Ro Actemra)	97	0	0	0	0	0
Tofacitinib (Xeljanz)	9	0	1	0	0	0
Ustekinumab (Stelara)	1	0	6	0	14	1
Vedolizumab (Entyvio)	0	0	0	0	22	38